What is the prevalence of Langerhans cell histiocytosis in young adults around 28 years of age?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 6, 2026 • View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Prevalence of Langerhans Cell Histiocytosis in Young Adults (~28 Years Old)

Langerhans cell histiocytosis is extremely rare in young adults around 28 years of age, with an incidence of approximately 1.06 per million adults aged ≥15 years, translating to a prevalence of roughly 10 per million persons in the general population. 1

Epidemiological Data

The most robust population-based data comes from the English National Cancer Registration Dataset (2013-2019), which provides the following key statistics:

  • Incidence in adults (≥15 years): 1.06 per million (95% CI 0.94-1.18) 1
  • Overall prevalence: 9.95 per million persons (95% CI 9.14-10.81) at the end of 2019 1
  • Age distribution: LCH can occur at any age, though approximately 49% of cases occur in children under 15 years 1

For context, a 28-year-old falls within the adult population where LCH incidence is substantially lower than in children (4.46 per million in children vs. 1.06 per million in adults ≥15 years). 1

Clinical Context for Young Adults

The Mayo Clinic consensus guidelines note that while Erdheim-Chester disease primarily affects young adults with a median age of 45 years, LCH may be seen across all age groups without a specific predilection for the 28-year age range. 2

Important caveat: The annual incidence of all histiocytic neoplasms combined is less than 5 cases per million population, making LCH an orphan disease that poses significant diagnostic challenges due to its rarity and diverse clinical manifestations. 2

Survival and Long-term Outcomes in Young Adults

Young adults with LCH have favorable outcomes:

  • 1-year overall survival in adults: 90% (95% CI 87%-93%) 1
  • 5-year overall survival: 88.7% 3
  • Age-related mortality risk: Individuals diagnosed before age 55 have a standardized mortality ratio of 5.94 compared to the general population, indicating significantly elevated mortality risk even in younger patients 3

The relatively low prevalence combined with diagnostic delays (due to diverse clinical presentations mimicking other conditions) means that clinicians should maintain a high index of suspicion when encountering unexplained multisystem disease or unusual bone lesions in this age group. 2

References

2
Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Related Questions

Which worldwide medical centers conduct research and clinical trials on Langerhans‑cell histiocytosis (LCH), is there a patient registry for LCH, and how can we establish a facility to study LCH and other liquid tumors?
What is the prevalence of scalp‑only Langerhans cell histiocytosis presenting with cutaneous lesions in 28‑year‑old adults?
What is the recommended evaluation and management for recurrence of Langerhans cell histiocytosis presenting as scalp skin lesions in a 28‑year‑old adult?
What is the Bexxly Harmonia healing frequency device, and is it indicated or beneficial for treating Langerhans Cell Histiocytosis, including hepatic involvement?
What is the pathophysiology of Langerhans cell histiocytosis?
How should I titrate a levothyroxine (synthetic T4) dose of 50 µg orally daily for a thyroid‑stimulating hormone level of 5.64 mIU/L?
Can I taper off long‑term 3 mg nightly lunesta (eszopiclone) and add ramelteon (Rozerem) during the taper?
A patient who had two recent molar extractions is now experiencing generalized malaise while on cephalexin 500 mg orally every 12 hours, with a slight rise in white‑blood‑cell count from 12.3 ×10⁹/L to 12.6 ×10⁹/L (high‑normal). Should I add an additional oral antibiotic or start intravenous antibiotics and repeat a CBC in three days?
What are the indications, dosing, and monitoring recommendations for using pramipexole as an adjunctive treatment in adults with major depressive disorder or bipolar depression who have failed adequate trials of other antidepressants?
What are the recommendations for prescribing metformin (generic) to women with polycystic ovary syndrome, including indications, starting dose, titration schedule, target maintenance dose, monitoring of renal function, and contraindications?
What is RDW (Red Cell Distribution Width) in a complete blood count (CBC)?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question